Author:
Englinger B,Mair M,Miklos W,Pirker C,Mohr T,van Schoonhoven S,Lötsch D,Körner W,Ferk F,Knasmüller S,Heffeter P,Keppler B K,Grusch M,Berger W
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Apps MG, Choi EH, Wheate NJ (2015) The state-of-play and future of platinum drugs. Endocr Relat Cancer 22 (4): R219–R233.
2. Bonfanti M, La Valle E, Fernandez Sousa Faro JM, Faircloth G, Caretti G, Mantovani R, D'Incalci M (1999) Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 14 (3): 179–186.
3. Bowden NA (2014) Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett 346 (2): 163–171.
4. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12 (3): 356–361.
5. Colmegna B, Uboldi S, Erba E, D'Incalci M (2014) Resistance to minor groove binders. Drug Discov Today Technol 11: 73–79.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献